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Introduction
The identification of Mendelian inheritance of increased vul-
nerability to breast and ovarian cancer drove a search for the 
genes involved, culminating in the discovery of two tumor sup-
pressor  genes,  BRCA1  and  BRCA2.  Germline  mutations  in 
BRCA1 are associated with an increased susceptibility to breast 
and ovarian cancer. Yet the biological functions underlying its 
role in carcinogenesis are still unclear. BRCA1 encodes a 1,863-
aa  tumor  suppressor  protein  that  contains  several  functional 
motifs, including an N-terminal RING (really interesting new 
gene) domain and a pair of 90 amino acid repeats at the C   
terminus called BRCA1 C-terminal (BRCT) domains (Fig. S1; 
Koonin et al., 1996).
BRCT domains have since been identified in other pro-
teins known to play a role in regulation of DNA damage re-
sponses and cell cycle checkpoint-mediated repair (Bork et al., 
1997; Glover et al., 2004). The paired BRCT domains have 
been shown to be important for nuclear targeting of BRCA1 
(Rodriguez  et  al.,  2004),  transcription  regulation  (Monteiro, 
2000), binding to DNA strand breaks, multimer formation at 
DNA fragment ends (Yamane et al., 2000), and altering chro-
matin structure (Hu et al., 1999). BRCT domains are essential 
for the tumor suppression activity of BRCA1 as protein trunca-
tions, and missense variants within these domains are associ-
ated with human breast and ovarian cancers (Glover, 2006). 
Moreover, they function as a phosphopeptide-binding module 
with a pSer-X-X-Phe phosphoserine specificity (Glover et al., 
2004) and may thus recruit phosphorylated signaling factors or 
complexes related to the DNA damage response.
Despite its central importance to tumor suppression activ-
ity, it is still uncertain how exactly BRCA1 works. The only 
known enzymatic activity for BRCA1 is that of an E3 ubiquitin 
ligase of the RING subclass when in a heterodimer with BARD1 
(Starita et al., 2004; Starita and Parvin, 2006). This complex can 
B
RCA1 C-terminal (BRCT) domains in BRCA1 are 
essential for tumor suppressor function, though the 
underlying mechanisms remain unclear. We identi-
fied ezrin, radixin, and moesin as BRCA1 BRCT domain–
interacting  proteins.  Ezrin–radixin–moesin  (ERM)  and 
F-actin colocalized with BRCA1 at the plasma membrane 
(PM) of cancer cells, especially at leading edges and focal 
adhesion sites. In stably expressing cancer cells, high   
levels  of  enhanced  green  fluorescent  protein  (EGFP)-
BRCA1
1634–1863 acted as a dominant-negative factor, dis-
placing  endogenous  BRCA1  from  the  PM.  This  led  to 
delayed cell spreading, increased spontaneous motility, and 
irregular monolayer wound healing. MCF-7 cells (intact 
BRCA1) showed lower motility than HCC1937 cells (trun-
cated BRCA1), but expression of EGFP-BRCA1
1634–1863 in 
MCF-7 increased motility. Conversely, full-length BRCA1 
expression in HCC1937 decreased motility but only if the 
protein  retained  ubiquitin  ligase  activity.  We  conclude 
that full-length BRCA1 is important for complete tumor 
suppressor activity via interaction of its BRCT domains 
with ERM at the PM, controlling spreading and motility 
of cancer cells via ubiquitin ligase activity.
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HeLa cell lysates. The BRCA1 protein was pulled down using 
anti-BRCA1 antibody–coupled beads (Fig. 1 C). A control pro-
tein (tryptase) was pulled down using antitryptase-coated beads, 
whereas mouse IgG1–coated beads were used as a negative 
control (Fig. 1 C). When the same samples were probed with an 
antiezrin antibody, the ezrin protein was only detected in the 
BRCA1 pull-down sample, whereas no signal was detected in 
either the tryptase or mouse IgG1 control samples (Fig. 1 C, 
bottom) or beads incubated with lysate but no antibody. These 
results confirmed a direct interaction between BRCA1 and ezrin 
in a native context.
BRCA1 colocalizes with the ezrin–radixin–
moesin (ERM) complex
ERM proteins are known to act as cross-linkers between the 
plasma membrane (PM) and the underlying F-actin cytoskele-
ton. To confirm the biochemical results and to investigate a   
potential involvement of BRCT domains in the ERM–F-actin 
interaction, immunofluorescence labeling was performed on 
cancer cells transiently expressing EGFP-CTD. All cell lines 
showed light microscope colocalization of the EGFP-CTD pro-
tein with both the ERM complex and F-actin at the PM (Figs. 2 
and S2, A and B). Higher magnification of membrane exten-
sions (Fig. 2 D, insets) frequently revealed the EGFP-CTD pro-
tein at sites where the ERM complex associated with F-actin. 
We next asked whether endogenous (full length) BRCA1 is also 
found at sites targeted by BRCT domains alone. Again, a simi-
lar distribution at the PM was seen by both light microscopy 
(Figs. S2 C and S3) and electron cryomicroscopy (Fig. S1 B). 
These results confirm the association of these proteins in a cel-
lular context.
Colocalization of EGFP-CTD with F-actin and the ERM 
complex was also observed at focal adhesions in residual mem-
brane sheets after mechanical shearing (Fig. 3 A), suggesting 
that  all  three  proteins  are  present  at  sites  of  cell  substrate 
adhesion.  Immunofluorescence  labeling  of  transiently  trans-
fected pEGFP-CTD HeLa cells for F-actin and anti-FAK dem-
onstrated the colocalization of all three proteins at PM ruffles 
(Fig. S4 A), focal adhesion plaques (Fig. S4 B), and at cellular 
footprints after mechanical cell removal (Fig. S4 C). A line scan 
across  the  PM  ruffles  showed  the  individual  distribution  of 
EGFP-CTD, F-actin, and ERM proteins (Fig. 3 B). Together 
with consecutive confocal xz sections (Fig. 3 C), we conclude 
that all three proteins colocalized in membrane extensions   
(microvilli) and adhesion points.
To exclude the possibility that high expression levels of a 
GFP-tagged protein were giving rise to nonspecific cytoplasmic 
filling extending into membrane ruffles, we analyzed two EGFP 
control proteins. HeLa cells transiently transfected with pEGFP-
neo  or  pEGFP-centrin  were  double  labeled  for  F-actin  and 
ERM. At high expression levels, we observed a cytoplasmic 
distribution of both soluble EGFP and EGFP-centrin extending 
into  membrane  ruffles.  Removing  the  soluble  pool  of  each 
EGFP fusion protein by saponin permeabilization before fixa-
tion and staining leaves behind only stably bound protein; focally 
targeted EGFP-CTD persisted after this treatment (Fig. S5 A), 
whereas EGFP-centrin is found at centrioles only (Fig. S5 B), 
auto-ubiquitinate the BRCA1 component, yet other function-
ally relevant targets have not been systematically studied.
We have previously shown that hyperphosphorylated 
BRCA1 is present in mitochondria, which is consistent with a 
function in mitochondrial DNA maintenance (Coene et al., 2005). 
To further investigate mitochondrial functions of BRCA1, we 
searched for interaction partners of the BRCT domains of BRCA1 
using ligand overlay blotting and coimmunoprecipitation. HeLa 
postnuclear membrane pellet fractions were used to exclude the 
large family of nuclear BRCT-containing proteins and their inter-
acting partners. This approach identified components of a   
mitochondrial import pathway, which will be described else-
where (unpublished data). These experiments also uncovered 
an unexpected association between BRCT domains and a family 
of cytoskeletal regulatory proteins, prompting the study of motility 
in cells in which these BRCA1 interactions were reduced by com-
petition or mutation. These analyses strongly implicate BRCA1 in 
the regulation of motility and migration of cancer cells.
Results
BRCA1 BRCT domains interact with ezrin, 
radixin, and moesin
To identify BRCT-interacting proteins, HeLa postnuclear mem-
brane pellet (P2) samples were resolved by 1D SDS-PAGE fol-
lowed by ligand overlay blotting using as a probe an EGFP-tagged 
BRCT region (1,634–1,863 aa) containing both BRCT domains 
(henceforth referred to as EGFP-CTD; Fig. S1). A doublet of 75 
and 80 kD was reproducibly detected using an EGFP-CTD– 
expressing HeLa lysate (Fig. 1 A, lane 3), whereas the detection 
of a third higher molecular mass band was not (Fig. 1 A, lane 1). 
The doublet was absent when incubating with either an EGFP–N-
terminal acidic domain of cortactin (EGFP-NTA) control lysate 
(Fig. 1 A, lane 2) or an untransfected lysate (not depicted). The 
75–80-kD doublet can therefore be regarded as a result of a spe-
cific interaction with the EGFP-CTD protein. The 80- and 75-kD 
bands (indicated by 1 and 2 in red in Fig. 1 A, lane 4) were ex-
cised, digested, and sequenced by liquid chromatography and tan-
dem mass spectrometry (LC-MS/MS), identifying ezrin, radixin, 
and moesin among other proteins with corresponding high Mas-
cot score values (Table S1, showing results for bands 1 and 2).
To refine the identification of BRCT-binding proteins pres-
ent within the 75–80-kD doublet, 2D electrophoresis ligand over-
lay blotting on HeLa P2 fractions was performed. The overlay 
blot revealed multiple spots in the region of 75–80 kD (Fig. 1 B, 
spots marked from 1 to 8). LC-MS/MS analysis demonstrated 
the presence of different isoforms of ezrin, radixin, and moesin 
with high Mascot score values (Table S2, showing results for 
spots 1–8), confirming the 1D ligand overlay results. Indeed, for 
all but one of these reactive spots, ezrin, radixin, or moesin repre-
sented the highest scoring and often sole protein identified.   
Under these denatured conditions, the BRCT domains of BRCA1 
interact independently with ezrin, radixin, and moesin.
Ezrin coimmunoprecipitates with BRCA1
To confirm a direct interaction between BRCA1 and ezrin in 
native  conditions,  we  performed  coimmunoprecipitation  on 499 BRCA1 regulates cell spreading and motility • Coene et al.
under these conditions were shown to be focal adhesion plaques 
in an experiment using an anti-FAK label to detect FAK (Fig. S6). 
Colocalization of EGFP-CTD, F-actin, and FAK was detected 
in these focal adhesion plaques. No such signal was observed 
and the control soluble EGFP is completely removed (Fig. S5 C). 
Saponin treatment damaged the membrane ruffles, resulting   
in the loss of both EGFP-CTD and ERM labeling at the PM 
(Fig. S5 A). The punctate structures labeled by EGFP-CTD   
Figure 1.  Direct BRCA1–ERM interaction detected by ligand overlay and coimmunoprecipitation. (A and B) HeLa P2 fractions were resolved by 1D SDS-
PAGE (A) or 2D electrophoresis (B), blotted, and probed with EGFP-CTD detected with anti-EGFP antibody. (A) A 75–80-kD doublet was reproducibly 
detected (lane 3), whereas a third higher molecular mass band was not (lane 1). No signal was detected in a parallel blot using the control HeLa lysate 
containing EGFP-NTA (lane 2). The 75–80-kD doublet (lane 4) was excised, trypsin digested, and sequenced by LC-MS/MS (Table S1). The red 1 and 2 
indicate the 80- and 75-kD bands, respectively. (B) 2D gel electrophoresis: multiple spots were detected in the 75–80-kD region. (a) SYPRO ruby staining; 
(b) Western blot; (c) detail of SYPRO ruby spots (1–8) cut out for LC-MS/MS analysis (Table S2, showing results for each spot). (C) Coimmunoprecipitation 
of ezrin with BRCA1. (top, 1) Lysate + beads + mouse anti-BRCA1 Ab1 (+), lysate + beads with no antibody (), and whole cell lysate (WCL) probed 
with mouse anti-BRCA1 Ab1; (2) lysate + beads + mouse antitryptase (+), lysate + beads with no antibody (), and whole cell lysate probed with mouse 
antitryptase; (3) beads + mouse IgG1 probed with anti–mouse IgG1. (bottom) The same samples as in the top immunoblotted for ezrin. Ezrin protein was 
only detected in the BRCA1 sample (4) when Ab1 was coupled to the beads (+). Beads with no antibody () and both the tryptase and mouse IgG1 control 
samples (5 and 6, respectively) were negative for ezrin. In replicate experiments, ezrin was reproducibly detected (mean band intensity in the BRCA1 pull-
down 20.0 [experiment 1] or 29.9 [experiment 2] vs. intensity in control pull-down 3.25 [experiment 1] or 1.03 [experiment 2]).JCB • VOLUME 192 • NUMBER 3 • 2011   500
Figure 2.  EGFP-CTD colocalization with ERM and F-actin. (A–D) CLSM of transiently EGFP-CTD–expressing HeLa (A, B, and D) and HCC1937 (C) cells 
labeled with TRITC-phalloidin (for F-actin) and anti-ezrin–radixin–moesin (ERM) antibody detected with Cy5. Colocalization was observed at the PM (A), 
leading edge (B), membrane ruffles (C), and PM extensions (D). (D) Higher magnifications of three regions (insets) show EGFP-CTD localization with respect 
to ERM and F-actin.501 BRCA1 regulates cell spreading and motility • Coene et al.
Figure 3.  EGFP-CTD localization in focal adhesion plaques. (A) HeLa cells transiently expressing EGFP-CTD were mechanically sheared and labeled with 
TRITC-phalloidin (for F-actin) and anti-ERM antibody (detected with Cy5). Colocalization of all three proteins was observed in the focal adhesion plaques 
and remaining structures. (B) Line scan across PM ruffles of a PMA-stimulated HeLa cell showing EGFP-CTD (green), F-actin (red), and ERM (blue) distri-
bution. The white line in the top image indicates the position of the line scan shown beneath. (C) Consecutive CLSM xz sections of the PM region of a 
transiently EGFP-CTD–expressing HeLa cell labeled with TRITC-phalloidin and anti-ERM antibody (Cy5). Colocalization of all three labels was observed in 
membrane extensions and cell substrate adhesion points, resulting in a white color.JCB • VOLUME 192 • NUMBER 3 • 2011   502
Ameer-Beg,  2004;  Peter  et  al.,  2005)  on  transiently  EGFP-
CTD–expressing HeLa cells, in which FRET was confirmed by 
measuring a shortened lifetime of the donor (EGFP-CTD) in the 
presence of an acceptor (Cy3, which was used to detect ERM; 
Fig. 4, D–F).
PMA and cytochalasin B affect F-actin, 
ERM, and EGFP-CTD behavior
To study the influence of motility on the behavior of BRCA1   
at  the  PM,  we  induced  cell  motility  by  PMA  stimulation   
(Nomura et al., 2007) and inhibited cell motility by cytochala-
sin B treatment (Haynes and Weller, 1978). Double labeling 
for ERM and F-actin in HeLa cells transiently expressing EGFP-
CTD (Fig. 5 A) showed an apparent increase in colocaliza-
tion of all three proteins at the PM ruffles after PMA treatment, 
suggesting that BRCT domain recruitment may be increased 
by this treatment, and thus, BRCA1 may have an involve-
ment in cell motility. To discard the possibility of a fixation 
for  either  soluble  EGFP  or  EGFP-centrin,  confirming  the   
specificity of the EGFP-CTD construct and the reliability of its 
subcellular localization. BRCA1 is thus positioned to have a 
role in membrane–cytoskeletal interactions with possible func-
tional consequences.
BRCA1 BRCT domains interact with native 
ezrin, radixin, and moesin: FLIM/FRET
To confirm a direct BRCA1–ERM cellular interaction, we used 
two resonant energy transfer methods. We performed acceptor 
photobleach fluorescence resonance energy transfer (FRET) on 
both transiently EGFP-CTD–expressing HeLa cells and HeLa 
cells labeled for endogenous BRCA1. Significant FRET was 
detected between labeled endogenous BRCA1 and ERM at the 
PM (mean FRET efficiency of 5.6%, P < 0.05; Fig. 4, A–C),   
indicating the two proteins are within nanometers of each other 
and most probably interacting. This finding was confirmed by 
fluorescence  lifetime  imaging  microscopy  (FLIM;  Peter  and 
Figure 4.  FRET analyses of BRCA1 and its interacting partners at the PM. 
(A) Acceptor photobleach FRET on PMA-stimulated HeLa cells. Endogenous 
BRCA1 was detected using Alexa Fluor 488 (donor); ERM was detected 
using Cy3 (acceptor). Increase in donor fluorescence was measured after 
photobleaching of the acceptor. (B) Pre- and postbleach images are shown 
for a representative ROI (white box in A). (C) Absolute increase in donor 
fluorescence mean FRET efficiency. 5.79% ± SEM = 0.85 (n = 23). A neg-
ative control (Cy3 acceptor targeted to the transferrin receptor) gave a 
mean FRET efficiency of 1.37 ± SEM = 0.97 (n = 15). P < 0.001 (t test). 
(D–F) FLIM-based FRET between EGFP-CTD and ERM (detected using Cy3) in 
untreated HeLa cells. Graph shows the percentage of pixels with a lifetime 
shortened enough to indicate a FRET efficiency (E) >20% (means ± SEM;   
n = 5). There is a significant difference (P < 0.05) between EGFP lifetime in 
the absence of an acceptor (representative cells shown in E) and when ERM-
Cy3 is present as an acceptor (representative cells shown in F). A positive 
control in which the Cy3 acceptor was targeted to EGFP-CTD using an anti-
GFP antibody and Cy3 is also shown (anti-GFP). (E and F) Bars, 10 µm.
Figure 5.  EGFP-CTD localization after PMA or cytochalasin B treatment. 
(A) Untreated (UNTR) transiently EGFP-CTD–expressing HeLa cells labeled 
with TRITC-phalloidin (for F-actin) and anti-ERM antibody (detected with 
Cy5) showed discrete colocalization at the PM (left), whereas enhanced 
colocalization was observed at the leading edges of the cell after PMA 
stimulation, resulting in a white color (right). (B) Cytochalasin B treatment 
of transiently EGFP-CTD–expressing HeLa cells followed by labeling with 
TRITC-phalloidin  for  F-actin  and  anti-ERM  antibody  (Cy5).  The  merged 
CLSM image confirms the presence of distinct structures containing all three 
proteins at the PM (arrows).503 BRCA1 regulates cell spreading and motility • Coene et al.
antibody pair) and an anti-pSer988 BRCA1 antibody on CHO–
wild-type (WT) and CHO cells highly expressing EGFP-CTD 
(CHO-High). The detection of BRCA1 in CHO cells was con-
firmed by Western blotting (Fig. S1 C). Single planes from con-
focal z stacks showed that, in CHO-WT, endogenous BRCA1 
was concentrated along the PM, colocalizing with F-actin   
(Fig. 6 A). In the CHO-High cells, however, endogenous BRCA1 
was absent in most places along the PM where EGFP-CTD was 
strongly expressed.
We then quantified the displacement of endogenous BRCA1 
protein using a MetaMorph macro to calculate colocalization in 
every plane of multiple z stacks. Mean intensity projection of   
z stacks showed an obvious endogenous BRCA1 signal at the 
defined PM region for CHO-WT, whereas a clearly diminished 
signal was seen for CHO-High (Fig. 6 B). After analyzing   
the colocalization overlap parameters for every image plane in   
multiple z stacks for both CHO-WT and CHO-High, a mean of   
75% of endogenous BRCA1 was found to overlap with F-actin 
for CHO-WT, whereas for CHO-High a mean value of only 
60% was found (Fig. 6 C). The individual colocalization values 
artifact, we used native GFP fluorescence from our fusion 
protein for time-lapse imaging in living cells. These experi-
ments confirmed an association of EGFP-CTD with highly 
dynamic membrane ruffles (Video 1).
After cytochalasin B treatment, double labeling of HeLa 
cells transiently expressing EGFP-CTD showed colocalization 
of EGFP-CTD with F-actin and ERM at distinct patches at the 
PM (Fig. 5 B, arrows). The F-actin signal was absent except in 
those patches, suggesting that this pool may be protected from 
depolymerization by formation of a complex including EGFP-
CTD and ERM.
EGFP-CTD competes with  
endogenous BRCA1
Both endogenous BRCA1 and EGFP-CTD proteins associated 
with the ERM complex and F-actin. This prompted us to specu-
late that the recombinant C-terminal fragment might compete 
for  ERM  and/or  F-actin  binding  and  displace  endogenous 
BRCA1 protein. To test this, we used TRITC-phalloidin to label 
F-actin (to prevent possible steric hindrance by an additional 
Figure 6.  Displacement of endogenous BRCA1. (A) CLSM of PMA-stimulated CHO–wild type (CHO-WT) and CHO cells stably expressing high levels of 
EGFP-CTD (CHO-High) labeled with TRITC-phalloidin and anti-Ser988 BRCA1 antibody (Alexa Fluor 647). Pronounced PM colocalization of endogenous 
BRCA1 and F-actin was observed in CHO-WT (left). In CHO-High, PM colocalization of EGFP-CTD and F-actin was observed, whereas endogenous BRCA1 
was absent (right). The endogenous BRCA1 distribution in the cytoplasm remained unchanged. Bars, 5 µm. (B) Mean intensity z projection of representa-
tive TRITC-phalloidin– and anti-Ser988 BRCA1 antibody (Alexa Fluor 647)–labeled CHO-WT and CHO-High z stacks. PM colocalization of endogenous 
BRCA1 and F-actin was prominent in CHO-WT cells but clearly reduced in CHO-High cells. The marked white outlines indicate the selected area for 
calculation of colocalization parameters. (C) Quantitative displacement graph showing the distribution of all colocalization percentage values of Ser988 
BRCA1 over F-actin from each plane of seven individual z stacks per CHO cell type. Overlap of Ser988 BRCA1 with F-actin is higher in CHO-WT than 
in CHO-High: CHO-WT, mean = 74.97 ± SEM = 1.49 (n = 57); CHO-High, mean = 61.17 ± SEM = 2.791 (n = 48). Horizontal lines indicate means. 
Nonparametric two-tailed Mann–Whitney test, P < 0.001; unpaired two-tailed t test with Welch’s correction, P < 0.001.JCB • VOLUME 192 • NUMBER 3 • 2011   504
slower than either HCC1937 (P < 0.01) or MCF-7–High cells   
(P < 0.01), whereas HCC1937 moved slower than MCF-7–High 
cells (P < 0.01; Fig. 7 B). In addition, MCF-7–High and HCC1937 
had a similar speed distribution to CHO-High, whereas the   
MCF-7 cells showed a similar distribution to CHO-WT and   
CHO-Low (Fig. 7 D). Thus, the effects of EGFP-CTD expression 
seen in CHO cell lines can be extrapolated to a human cell line   
expressing endogenous BRCA1.
To ensure the dominant-negative effect of the EGFP-CTD 
fusion is solely caused by targeting and displacing BRCA1 and 
not another BRCT domain–containing protein, we analyzed the 
motility behavior of both native HCC1937 cells and HCC1937 
cells stably expressing full-length BRCA1 (HCC1937 + WT 
BRCA1). HCC1937 cells have been shown to have one BRCA1-
null allele and to carry a BRCA1 mutation (5382insC) in the 
second allele, which leads to a premature stop codon truncating 
the protein at residue 1,829 (Fig. S1 A; Tomlinson et al., 1998). 
This mutation resulted in very aggressive early onset breast can-
cer. Comparing mean speeds for both cell types, we found that 
the rescued HCC1937 + WT BRCA1 cells moved significantly 
slower than the native HCC1937 cell line, which only contained 
the truncated BRCA1 protein (P < 0.01; Figs. 7, B and D; and 8 C, 
top).  Thus,  restoring  full-length  BRCA1  in  HCC1937  cells 
clearly reversed its original highly motile phenotype into a more 
static one, which is now comparable with cells expressing WT 
BRCA1, including the low motile nonmetastatic MCF-7 cell 
line. We conclude that the observed changes in phenotype upon 
overexpression of the EGFP-CTD fragment are caused by spe-
cific displacement of the BRCA1 protein.
A corollary of this conclusion is that there should be no 
dominant-negative effect from the expression of EGFP-CTD in 
HCC1937 cells, which lack a functional BRCA1 protein for dis-
placement.  Therefore,  we  compared  the  motility  behavior  of 
HCC1937 cells with that of a stable HCC1937–EGFP-CTD cell 
line. HCC1937 and HCC1937–EGFP-CTD showed similar speed 
distribution and indistinguishable mean speeds of 0.50 (± SEM < 
0.01) and 0.52 µm/min (± SEM < 0.01), respectively (Fig. 8 B).
Cell tracks monitored over a time period of 1 h for both 
CHO and MCF-7 (WT vs. High) can be seen in Fig. 7 E. The 
stable high-expressing cell lines showed enhanced motility ver-
sus their WT counterparts. As an additional control, we included 
a  single-cell  motility  analysis  on  cells  expressing  unrelated 
EGFP fusion proteins, for example HeLa cells transiently trans-
fected to express EGFP-centrin. Cytoplasmic accumulation of 
this fusion protein, even at high expression levels, did not inter-
fere with the motility behavior of the cells (Fig. 8 A). The mean 
speed of HeLa cells treated with the transfection reagent only 
and HeLa cells transiently expressing EGFP-centrin were 0.2   
(± SEM < 0.01) and 0.18 µm/min (± SEM < 0.01), respectively.
Finally, to achieve a more mechanistic insight, we focused 
on the only known enzymatic activity of BRCA1 as an E3 ubiq-
uitin ligase, making use of a point mutation (I26A) that abrogates 
this activity. We compared the motility behavior of HCC1937, 
HCC1937-WT, and HCC1937-I26A. Cells were manually tracked 
in time-lapse videos of low density cultures and analyzed as de-
scribed for CHO cells. Mean speed measurements revealed that 
restoring HCC1937 with a full-length, but ubiquitin ligase–dead, 
were mainly concentrated around the mean for CHO-WT, whereas 
the distribution was more dispersed with lower colocalization   
values for CHO-High. This difference was highly significant   
(P < 0.001 by either a nonparametric two-tailed Mann–Whitney 
test or an unpaired two-tailed t test with Welch’s correction).
These data demonstrate competition between the EGFP-
CTD chimera and endogenous BRCA1, resulting in displace-
ment of endogenous BRCA1 protein. The specificity of this 
competition and displacement is further addressed later in this 
paper (see BRCA1 plays a role in single-cell motility). Because 
EGFP-CTD lacks the other domains of BRCA1, such a dis-
placement event might have functional consequences. To assess 
this, we performed three different functional assays to screen 
for potential abnormalities in cellular behavior.
BRCA1 plays a role in cell spreading
We investigated the role of BRCA1 in cell spreading by deter-
mining the percentage of spread out cells shortly after seeding. 
The results showed that, after seeding and a 3-h attachment time 
period, more CHO-WT cells were spread out than CHO-High 
(P < 0.01; Fig. S1 D) and CHO cells expressing low levels of 
EGFP-CTD (CHO-Low; P < 0.01; Fig. 7 A). Cells fixed 24 h 
after seeding no longer showed differences in spreading, sug-
gesting there is no absolute deficit but rather a kinetic differ-
ence. We next measured each cell area in populations of the 
different CHO cell types. The mean area of rounded up cells in 
CHO-WT, CHO-Low, and CHO-High was 351 (± SEM = 7), 
319 (± SEM = 6), and 320 (± SEM = 5) pixels, respectively, 
whereas the mean area of the spread out cells in CHO-WT, CHO-
Low, and CHO-High was 635 (± SEM = 40), 564 (± SEM = 18), 
and 547 (± SEM = 23) pixels, respectively. These results suggest 
that BRCA1 may be involved in regulating the initial spreading 
of transformed cells.
BRCA1 plays a role in single-cell motility
We next studied the spontaneous motility behavior of individ-
ual  cells.  CHO-WT,  CHO-High,  and  CHO-Low  cells  were 
manually tracked in time-lapse videos of low density cultures. 
Mean speed values suggested a dose effect with CHO-WT 
moving slower than CHO-Low (P < 0.05) and significantly 
slower than CHO-High (P < 0.01) cell populations (Fig. 7 B). 
CHO-Low  also  moved  significantly  slower  than  the  CHO-
High cell line (P < 0.01).
Speed frequency histograms showed that CHO-WT and 
CHO-Low had similar motility behavior, whereas CHO-High 
exhibited a different speed pattern (Fig. 7 C). In addition, we   
analyzed motility of the unsorted CHO–EGFP-CTD cell popula-
tion. This showed a similar mean speed to CHO-High (P = 0.5) 
and a comparable speed frequency histogram (unpublished data). 
Overall, these results showed that CHO-High move faster than 
CHO-WT and CHO-Low cells. This strongly suggests that inter-
fering with endogenous BRCA1 leads to enhanced cell motility 
and that BRCA1 may play a role in controlling cell movement.
To confirm this finding in human breast cancer cell lines with 
(MCF-7) or without (HCC1937) functional BRCA1, we repeated 
the motility experiment on HCC1937, MCF-7, and MCF-7 cells 
highly expressing EGFP-CTD (MCF-7–High). MCF-7 moved 505 BRCA1 regulates cell spreading and motility • Coene et al.
Figure 7.  Functional assays on CHO, MCF-7, HCC1937, and HCC1937 + WT BRCA1 cell lines. (A) Cell spreading: the percentage of spread out cells per field 
at 3 h after seeding for CHO–wild type (CHO-WT) and CHO stably expressing low (CHO-Low) or high (CHO-High) levels of EGFP-CTD (means ± SD; n = 5).   
Each pairwise comparison by t test gave P < 0.01. (B) Table comparing mean speeds for different cell populations. CHO-WT and MCF-7 moved slower than 
their high expressing counterparts CHO-High and MCF-7–High. MCF-7–High moved faster than HCC1937. HCC1937 cells rescued with full-length BRCA1 
(HCC1937 + WT BRCA1) displayed a highly significant lower mean speed than their native HCC1937 counterpart. All but one of the mean speed differences 
were highly significant (P < 0.01). There is no difference in the mean speed of HCC1937 + WT BRCA1 versus MCF-7 (P = 0.1). Means ± SEM for CHO-WT,   
CHO-Low, CHO-High, HCC1937 + WT, MCF-7, HCC1937, and MCF-7–High are 0.38 ± 0.01, 0.42 ± 0.01, 0.84 ± 0.02, 0.29 ± 0.01, 0.32 ± 0.01,   
0.52 ± 0.01, and 0.89 ± 0.02, respectively (n = 4). (C) Motility of CHO cell populations: a speed frequency histogram is shown for CHO-WT, CHO-High,   
and CHO-Low cell types (means ± SD; n = 4). The CHO-High moved faster than CHO-WT and CHO-Low. CHO-WT and CHO-Low behaved similarly.   
(D) Motility of MCF-7, HCC1937, HCC1937 + WT BRCA1, and MCF-7–High cell populations: a speed frequency histogram is shown for MCF-7, HCC1937, 
HCC1937 + WT BRCA1, and MCF-7–High cells (means ± SD; n = 4). HCC1937 and MCF-7–High cells moved faster than HCC1937 + WT BRCA1 and 
MCF-7. MCF-7–High cells moved faster than HCC1937. Restoring full-length BRCA1 in HCC1937 reversed the hypermotility pattern. X-axis values are   
upper bounds for each speed bin. (E) Cell tracks for CHO-WT, CHO-High, MCF-7, and MCF-7–High cells are shown, including phase contrast and EGFP-
CTD expression. CHO-WT and MCF-7 moved less far than their high expressing counterparts over this 1-h time period imaged at 2-min intervals. (F) Wound 
healing of CHO-WT, unsorted CHO–EGFP-CTD, and CHO-High cell monolayers. PVIs from seven independent wounds are presented for each cell type. The 
CHO-High population displayed the highest PVI values, which were correlated with a highly irregular wound margin. CHO-WT and unsorted CHO–EGFP-
CTD showed a more regular behavior. Means for CHO-WT, unsorted CHO–EGFP-CTD, and CHO-High were 51, 73, and 209, respectively (horizontal lines). 
Nonparametric two-tailed Mann–Whitney U tests gave P < 0.05 (CHO-WT vs. unsorted CHO–EGFP-CTD) and P < 0.001 (CHO-WT vs. CHO-High; n = 7).JCB • VOLUME 192 • NUMBER 3 • 2011   506
To  test  whether  or  not  we  could  now  reverse  the  low   
motility phenotype of MCF-7, we made stable lines of MCF-7 
reconstituted with the full-length BRCA1 (MCF-7–WT) and 
the I26A mutation in full-length BRCA1 (MCF-7–I26A) and 
repeated the same experiment. MCF-7 and MCF-7–WT showed 
BRCA1 mutant (HCC1937-I26A) resulted in an even higher mean 
speed than HCC1937 (Fig. 8 C, top left). Rescued HCC1937-WT 
moved  slower  than  HCC1937  cells,  whereas  HCC1937-I26A 
moved even faster than the already highly motile native HCC1937 
cell line (Fig. 8 C, top right).
Figure 8.  Functional assays on different CHO, HCC1937, and HeLa cell populations. (A) Speed frequency histogram for HeLa versus HeLa–EGFP-centrin 
cells (means ± SEM; n = 12). X-axis values are upper bounds for each speed bin. Overexpression of EGFP-centrin did not affect the motility behavior of 
HeLa cells. (B) Speed frequency histogram for HCC1937 versus HCC1937–EGFP-CTD (means ± SEM; n = 8). Both cell lines showed indistinguishable motility.   
(C) Single-cell motility assay on human breast cancer cell lines. Graphs showing the mean speed (means ± SEM; n = 120) for different cell populations (left). 
HCC1937 rescued with full-length BRCA1 (HCC1937-WT) displayed a highly significant lower mean speed than their native HCC1937 counterpart.   
On the contrary, HCC1937 rescued with full-length ubiquitin ligase–dead BRCA1 (HCC1937-I26A) displayed a highly significant increase in mean speed 
over HCC1937. No change in mean speed is seen in MCF-7 cell lines expressing full-length BRCA1, but MCF-7 expressing the ubiquitin ligase–dead muta-
tion (MCF-7–I26A) displayed a highly significant higher mean speed than their native MCF-7 counterpart. All of the mean speed differences for HCC1937 
cell types rendered P < 0.01; all of the mean speed differences for MCF-7 cell types rendered P < 0.01; the mean speed difference of HCC1937-WT versus 
MCF-7 was not significant (P = 0.3). Speed frequency histograms for different cell populations (right). HCC1937 shows higher motility than MCF-7; express-
ing full-length BRCA1 in HCC1937 resulted in a left shift of the motility pattern to resemble that of MCF-7 cells. Expression of the I26A mutant in either cell 
type gave a right shift to increased motility, higher than the native or BRCA1-expressing cells. X-axis values are upper bounds for each speed bin.507 BRCA1 regulates cell spreading and motility • Coene et al.
inhibitor that competes with the endogenous BRCA1 protein 
for ERM and/or F-actin binding sites, leading to abnormalities 
in cell spreading and cell motility, changing the cell behavior.
Discussion
Since the discovery of the BRCA1 gene, multiple functions have 
been assigned to the protein it encodes. Yet the biological func-
tions underlying its role in carcinogenesis remain to be fully 
elucidated. Here, we reveal some unexpected, yet potentially 
very important, functions for the BRCA1 protein in regulating 
cell spreading and motility, which have significant implications 
for tumor invasion and metastasis.
Partners interacting with  
BRCA1 BRCT domains
We  demonstrated  a  specific  interaction  between  the  paired 
BRCT domains of BRCA1 and three proteins from the ERM 
family, namely ezrin, radixin, and moesin. The paired BRCT 
domain fragment recognizes each of these proteins indepen-
dently rather than a complex between them. The proteins of   
the ERM family have structural resemblances but are still dis-
tinct. However, they all share the FERM (band 4.1, ezrin, radixin, 
and moesin) domain, an N-terminal domain highly conserved in 
this band 4.1 subclass (Chishti et al., 1998; Bretscher et al., 
2002), which includes talin and FAK, both of which are in-
volved in cell motility regulation (Diakowski et al., 2006). We 
do not know whether the BRCT domains of BRCA1 interact 
with the FERM domain in these proteins, but note that we did 
not detect other FERM domain–containing proteins in our li-
gand overlay experiments.
Intracellular colocalization of  
BRCA1 with ERM and F-actin
In contrast to adult tissues, cultured cell lines usually express all 
three ERM proteins, which are concentrated in actin-rich cell 
surface structures, such as microvilli, focal adhesions, and 
membrane ruffles (Sato et al., 1992). Confocal laser-scanning 
microscopy (CLSM) revealed a widespread subcellular distri-
bution of the BRCT domain fusion protein in multiple cell types 
but also confirmed a significant colocalization with ERM fam-
ily proteins at PM sites. Subsequent examination of full-length 
BRCA1 distribution showed the endogenous protein also pres-
ent at these ERM- and F-actin–enriched PM sites. Although   
intracellular association between BRCA1 and cytoskeletal fea-
tures had been described previously (Coene et al., 2005), the 
data reported here characterize a new subcellular localization 
for BRCA1 at the PM and reveal associations with PM ruffles, 
leading edges, microvilli, and focal adhesion plaques. Intra-
cellular FRET results strongly suggest an association with the 
ERM complex and F-actin.
The ERM complex controls and regulates cell adhesion, 
spreading, and motility, and ezrin has been shown to be a key 
component in tumor metastasis (Hunter, 2004) because of its 
interaction  with  adhesion  molecules  such  as  CD43,  CD44, 
ICAM-1, and ICAM-2 (Heiska et al., 1998; Yonemura et al., 
1998) implicated in cell migration and metastasis (Tang and 
similar slow motility, whereas MCF-7–I26A showed increased 
motility (Fig. 8 C, bottom). Thus, additional expression of WT 
BRCA1 in MCF-7 cells already expressing functional endoge-
nous  BRCA1  did  not  affect  motility,  whereas  expression  of 
BRCA1 bearing an inactivating point mutation lead to a pheno-
type of increased motility, suggesting a dominant-negative   
effect of the enzymatically inactive I26A mutant protein. These 
observations suggest that interfering with either the subcellular 
targeting or E3 ubiquitin ligase activity of BRCA1 protein leads 
to enhanced cell motility, which is consistent with an important 
role for BRCA1-dependent ubiquitination in the regulation of 
cell spreading and motility.
BRCA1 plays a role in wound healing
To examine the consequences of increased mobility on cell pop-
ulations rather than single cells, we turned to a widely used   
in vitro wound-healing model. By growing cells to a near conflu-
ent monolayer, scraping a wound in the monolayer, and follow-
ing the healing of the wound by time-lapse microscopy, we 
were able to assess BRCA1 function in modulating the influ-
ence of cell–cell contact and external stimuli on cell motility. 
The simplest outcome measure in this assay is an assessment of 
wound closure at a predefined end point. No significant differ-
ence  was  observed  between  the  different  CHO  populations 
when determining the percentage of gap closure after 12 h (un-
published data). Nonetheless, some individual cells expressing 
EGFP-CTD (either from unsorted CHO–EGFP-CTD or flow-
sorted CHO-High cell populations) exhibited strikingly abnor-
mal behavior. Their movement was haphazard and faster than 
other cells in the population. Of those presenting abnormal mo-
tility behavior, some were located in deeper cell layers relative 
to the wound and exhibited enhanced invasive capacity (Video 2, 
orange cell track). Other cells seemed to have lost cell–cell con-
tact and attachment with the underlying cell layers and moved 
into the gap as single cells (Video 2, pink cell tracks). The latter 
behavior was rare in the CHO-WT population. Loss of cell–cell 
contact and independent migration of separated cells into the 
wound space was most apparent in CHO-High cells. As a result, 
the perimeter of wounds in CHO-High monolayers appeared 
discontinuous  and  irregular  in  contrast  to  the  more  uniform 
boundary of wounds in CHO-WT (Video 3).
To quantify these wound edge differences, we defined a 
perimeter variability index (PVI) based on changes in the length 
of a semiautomated trace along the wound perimeter over time. 
We wrote a second journal (macro) to handle this calculation   
for all 300 images of each time-lapse video (Fig. 7 F). The PVI 
values for CHO-WT replicates were closely grouped together 
with a low mean of 51.4, reflecting a highly reproducible regu-
lar wound perimeter morphology, whereas the CHO-High cells 
presented more variability in the wound perimeter over time, 
hence a higher mean PVI value of 208.9. The unsorted CHO–
EGFP-CTD cell type showed a distribution similar to CHO-WT 
with a mean value of 72.9. Nonparametric two-tailed Mann–
Whitney U tests gave P < 0.05 for the comparison between 
CHO-WT and unsorted CHO–EGFP-CTD and P < 0.001 for the 
comparison between CHO-WT and CHO-High. These findings 
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lack both BRCT domains developed various tumors, including 
breast cancer. The breast tumor phenotype showed invasive to 
highly invasive borders as well as pushing margins (Ludwig   
et al., 2001). These findings suggest that, at least in mice, 
Bard1 and Brca1 seem to participate in regulating cell spreading 
and motility but also support our results and hypothesis that 
BRCT domains of BRCA1 are needed to regulate cell motil-
ity successfully.
Furthermore, in population-based experiments, it was ob-
served that the majority of the BRCA1 breast cancers displayed 
histological grade III (Brekelmans et al., 2007). This is an im-
portant finding because high histological grade is usually asso-
ciated with a greater propensity to distant metastasis.
Unselected invasive breast cancers have showed both re-
duced BRCA1 mRNA and protein expressions when compared 
with noninvasive cancers and benign tissues (Thompson et al., 
1995; Taylor et al., 1998; Seery et al., 1999). A significant asso-
ciation between low BRCA1 expression levels and the develop-
ment  of  distant  metastases  and  acquisition  of  an  invasive 
phenotype has also been reported (Seery et al., 1999; Xu et al., 
1999). This suggests a role for BRCA1 as a suppressor for   
invasion. Again, all these observations are consistent with our 
hypothesis that BRCA1 is needed to control cell motility and 
inhibit metastasis and invasion.
Invasion and metastasis are known to be complex biological 
processes. The first event to happen is the detachment of cancer 
cells from the original tumor followed in a later stage by inva-
sion. Our results confirmed these single-cell detachment and 
loss of cell–cell contact events as well as the invasion capacity 
when we interfered with the endogenous BRCA1 protein using 
the EGFP-CTD protein as a dominant-negative factor (Videos 2 
and 3). These time-lapse videos provide evidence that interfer-
ing with endogenous BRCA1 promotes an invasive phenotype.
BRCA1 function at the PM
The only enzymatic role that has been identified for BRCA1 is 
that of E3 ubiquitin ligase activity in a heterodimer composed 
of BRCA1 and BARD1 (a protein structurally and functionally 
related to BRCA1), and experiments support a role for BRCA1 
in the ubiquitination pathway (Starita and Parvin, 2006). The 
importance of an intact BRCA1 N terminus, where the RING 
domain ligase active site is found, in tumor suppression has 
been shown before, but the underlying mechanisms are un-
clear. We demonstrate that intact E3 ubiquitin ligase activity of 
BRCA1 is needed to control motility. Moreover, this activity 
needs to be targeted to ERM and F-actin–containing sites at the 
PM. Loss of BRCA1 protein from these sites or loss of ubiqui-
tin ligase activity can promote increased motility with implica-
tions for tumorigenesis.
Different forms of ubiquitin modification exist, each of 
them  playing  roles  in  diverse  cellular  processes  (Weissman, 
2001).  Monoubiquitination  is  regarded  as  a  major  signaling 
event that can mediate endocytosis and, thus, regulate turnover 
of PM proteins. The interaction of ERM proteins with the BRCT 
domains of BRCA1 raises the intriguing possibility that acti-
vated  ERM  proteins  could  themselves  be  normal  targets  of 
BRCA1 E3 ubiquitin ligase activity. If so, loss of this activity 
Honn, 1994–1995; Rosette et al., 2005). Ezrin and potentially 
other members of the ERM family have key roles in transferring 
signals  from  metastasis-associated  cell  surface  molecules  to 
other downstream signal transduction components (Bretscher   
et al., 2002). The association of BRCA1 with the key regulators 
of cell adhesion, spreading, and motility suggests that BRCA1 
may act up- or downstream in their signaling pathways.
Consequences of displacing  
endogenous BRCA1
Endogenous BRCA1 and the EGFP-CTD fusion protein com-
pete for the same binding sites on the ERM–F-actin complex at 
the PM. Expressed EGFP-CTD displaces endogenous BRCA1 
and behaves as a dominant-negative inhibitor, leading to distur-
bances in cell spreading and motility and giving rise to a change 
in wound-healing behavior. The use of early passage number 
stable EGFP-CTD cell lines with a stable EGFP-CTD expression 
level excluded the possibility that these altered phenotypes were 
a consequence of an acute displacement caused by a temporary 
EGFP-CTD overexpression during transient transfection.
However, BRCT domains are not unique to BRCA1 but 
have also been described in other proteins involved in cell cycle 
checkpoint-mediated repair and DNA damage response path-
ways. Thus, it is possible that the spreading, motility, and 
wound-healing  phenotypes  might  result  from  EGFP-CTD   
effects on another BRCT domain–containing protein. To ad-
dress this issue, we turned to human breast cancer cell lines 
with well-characterized BRCA1 status. We studied HCC1937 
cells containing only a truncated BRCA1 protein, HCC1937 
cells expressing the EGFP-CTD fusion protein, and restored 
HCC1937  cells  with  full-length  BRCA1.  Only  in  this  latter 
setup were we able to dramatically reverse its behavior from a 
high to a low motility phenotype similar to that of cells natu-
rally containing functional BRCA1, including CHO and HeLa 
as well as another breast cancer cell line MCF-7, known to be 
nonmetastatic. Finally, we repeated our observations on a stable 
MCF-7 cell line expressing EGFP-CTD and found as expected 
that this resulted in a hypermotile phenotype. Collectively, these 
results suggest that EGFP-CTD does indeed interfere with 
BRCA1  and  accounts  for  the  phenotypic  changes  observed. 
Furthermore, we conclude that both the N and C termini of the 
BRCA1 protein are needed to perform its role in regulating cell 
spreading and motility correctly.
Both N-terminal RING and C-terminal BRCT domains 
function as interaction modules and interact with proteins in-
volved in multiple pathways. The N-terminal RING finger   
of BRCA1 is known to interact with BARD1, its heterodimeric 
partner. If BRCA1 and BARD1 cooperate in the regulation of 
cell  motility,  one  would  expect  that  tumorigenic  mutations 
within either BRCA1 or BARD1, impairing the BRCA1–BARD1 
interaction, will influence cell spreading and motility. Interest-
ingly, repression of Bard1 induced complex phenotypic changes 
in mammary epithelial cells, which were suggestive of a pre-
malignant phenotype. Bard1-suppressed murine mammary epi-
thelial cells overcame contact inhibition, formed multiple cell 
layers, and expressed an invasive phenotype (Irminger-Finger   
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(Gene Pulser II; Bio-Rad Laboratories) at 250 V and 960 µF for 51.1 ms.   
A few days after electroporation, the cells were put under 600 µg/ml 
G418 selection.
Membrane fraction preparation
HeLa P2 fractions were prepared as previously described (Coene et al., 
2005) with minor modifications. Nearly confluent HeLa cells were washed 
with ice-cold PBS, scraped, and harvested. The pellet was resuspended in 
1 ml of isolation buffer (10 mM Tris-HCl, 10 mM NaCl, 1.5 mM MgCl2-
6H2O, 1 mM EDTA, 70 mM sucrose, and 210 mM mannitol, pH 7.5) with 
protease  inhibitors  (Roche)  and  homogenized  with  40  strokes  using  a 
Balch homogenizer (custom made by EMBL workshop) on ice. The mem-
brane fraction was collected by differential centrifugation, dissolved in   
25 mM Tris-HCl, pH 8.0, and 10 mM CaCl2-6H2O, and treated with   
50 ng/ml proteinase K (Fluka; Sigma-Aldrich) in 10 mM Tris-HCl, pH 8.0, 
and 1 mM CaCl2-6H2O for 30 min at RT. The reaction was stopped with 
10 mM PMSF for 10 min at RT. For 1D SDS-PAGE, samples were denatured 
by adding sample buffer with 100 mM DTT (Sigma-Aldrich) and heated for 
5  min  at  95°C  before  loading.  For  2D  electrophoresis,  samples  were   
acetone precipitated and redissolved in IEF solubilization buffer (7 M 
urea, 2 M thiourea, 2% [wt/vol] CHAPS, 65 mM DTT, 2.0% [wt/vol] am-
pholine  [IPG  buffer;  GE  Healthcare],  and  trace  bromophenol  blue 
[Sigma-Aldrich]).
1D and 2D ligand overlay blotting
For 1D SDS-PAGE, membrane fractions (equivalent to 10
6 cells per lane) 
were resolved by SDS-PAGE using standard techniques. The gel was either 
stained  with  Imperial  Protein  Stain  (Perbio  Science)  and  processed  for   
LC-MS/MS or blotted. Nitrocellulose membrane was incubated overnight 
with HeLa lysate. Untransfected, pEGFP-CTD–transfected (3.2 µg DNA per 
well of a 6-well plate), and pEGFP-NTA–transfected (3 µg DNA per well of a 
6-well plate) HeLa cell lysates were made using radioimmunoprecipitation 
assay  (RIPA)  buffer  (Millipore)  and  protease  inhibitor  cocktail  tablets 
(Roche) according to the manufacturer’s instructions. Goat polyclonal anti-
GFP  antibody  (dilution  1:5,000;  Abcam)  and  donkey  anti–goat  HRP- 
labeled secondary antibody (dilution 1:4,000; Jackson ImmunoResearch 
Laboratories, Inc.) were used for detection.
For 2D electrophoresis, immobilized gel strips (Immobiline Drystrip; 
GE Healthcare) of 13 cm and a linear pH gradient range, pH 3–10, were 
rehydrated in IEF solubilization buffer. Protein (150 µg/strip) was loaded 
from a cup on the cathodic end. Proteins were electrofocused as follows: 
30 min at 250 V, 3-h linear gradient at 250–8,000 V, and 14 h at 8,000 V, 
all at 20°C. IEF gel strips were equilibrated in 50 mM Tris-HCl, pH 8.8,   
6 M urea, 30% (vol/vol) glycerol, 2% (wt/vol) SDS, and 65 mM DTT for 
15 min followed by incubation in SDS equilibration buffer supplemented 
with 135 mM iodoacetamide (Fluka) for 15 min. Gel strips were placed 
onto the top of 10% SDS-PAGE and run at 8 W/gel for 2.5 h. 2D gels 
were either fixed in 10% (vol/vol) methanol and 7% (vol/vol) acetic acid 
and stained with SYPRO ruby (Sigma-Aldrich) for further imaging and spot 
excision or semidry transferred to nitrocellulose membrane and processed 
as described in the previous paragraph. For BRCA1 detection in CHO   
lysate on a Western blot, we used Ser988 (1:100) and Ser1497 (1:200) 
anti-BRCA1 antibodies (Santa Cruz Biotechnology, Inc.) as primary anti-
bodies and donkey anti–goat HRP-labeled secondary antibody (dilution 
1:4,000) for detection.
Coimmunoprecipitation
HeLa cells were treated with 150 nM PMA (Sigma-Aldrich) for 90 min at 
37°C and lysed on ice using RIPA buffer (Sigma-Aldrich) supplemented 
with 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 mM NaF, 1 mM PMSF, and 
1 mM Na3VO4. The lysate was rotated for 15 min at 4°C on an orbital 
rocker and centrifuged for 15 min at 14,000 g at 4°C. The supernatant 
was precleared by adding a 50% slurry of Protein A/G PLUS beads (Tebu-
Bio) and rotating for 30 min at 4°C. 5 mg/ml of cell lysate was incubated 
with 2 µg each of mouse anti-BRCA1 Ab1 (MS110; Oncogene Science–
Merck Chemicals), mouse antitryptase (AbCys), and mouse IgG1 pure 
(BD) antibodies and no antibody for 90 min at 4°C on an orbital shaker.   
A 50% slurry of Protein A/G PLUS beads was added overnight. Beads 
were washed three times with ice-cold RIPA buffer. Immunoprecipitated 
proteins were denatured by the addition of sample buffer, boiled for 5 min, 
resolved by 6% Tris-glycine SDS-PAGE, and analyzed by immunoblotting 
using mouse anti-BRCA1 Ab1 (1:50), mouse antitryptase (1:500), and rab-
bit antiezrin (1:1,000; Cell Signaling Technology) antibodies. For detec-
tion, we used goat anti–mouse HRP (Thermo Fisher Scientific) and goat 
anti–rabbit HRP (Dako) antibodies in combination with the SuperSignal 
might lead to an accumulation of ERM proteins at the cell sur-
face; we note that high expression of ezrin has been linked to 
high metastatic potential (Akisawa et al., 1999), supporting 
this hypothesis. This hypothesis, together with the fact that both 
intact N and C termini of BRCA1 are needed to successfully 
perform its ubiquitination function (Starita et al., 2004), fits 
closely with our displacement assay and the consequences for 
cell spreading and cell motility. The single-cell motility assays 
with HCC1937 versus MCF-7 add further strength to this   
hypothesis. Loss of even a few C-terminal residues of BRCA1 
might lead to an unstable BARD1–BRCA1 heterodimer, caus-
ing irregularities in the E3 ubiquitin ligase activity, which in 
turn could lead to a deregulation of the turnover/degradation   
of  PM  proteins.  This  would  explain  why  BRCA1-truncated 
HCC1937 cells displayed a higher mean speed than the MCF-7 
containing intact BRCA1.
An alternative, but not mutually exclusive, possibility is 
that PM-localized BRCA1 functions via an association with 
ERM proteins that interact with PM receptors. Ubiquitin ligase 
activity could target machinery or cargo in the endocytic path-
way and, thus, influence trafficking of PM receptors.
Until now, it remained unknown how BRCA1 might exert 
an effect on the invasion and migration of breast cancer cells.   
In light of the results reported here, we suggest a potential role 
for BRCA1 at the PM as an E3 ubiquitin ligase controlling the 
trafficking and/or turnover of specific PM receptors or proteins, 
involved in focal adhesion, cell–cell, and cell–matrix contacts. 
Modulation of the levels of such proteins, or their related down-
stream signaling pathways, may consequently regulate the inva-
sive and metastatic properties of tumor cells. Further research is 
needed both to pinpoint the relevant protein targets and to iden-
tify the signaling pathway involved.
Materials and methods
Cell lines
HeLa, a human cervix carcinoma cell line, and ECV304, a vascular endo-
thelial cell line, were cultured in DME with high glucose (4.5 g/liter),   
l-glutamine, and sodium pyruvate (PAA Laboratories GmbH) supplemented 
with 10% (vol/vol) FCS. HCC1937 is a primary breast ductal carcinoma 
cell line cultured in RPMI 1640 medium with l-glutamine and 1 mM sodium 
pyruvate supplemented with 10% (vol/vol) FCS. CHO is a CHO cell line 
cultured in Ham’s F12 medium with  l-glutamine and supplemented with 
10% (vol/vol) FCS. MCF-7 is a human breast adenocarcinoma cell line 
cultured in MEM with Earle’s salts, without l-glutamine, supplemented with 
1% (vol/vol) nonessential amino acids and 10% (vol/vol) FCS. All cell 
lines were obtained from the American Type Culture Collection.
Stable cell lines
CHO and MCF-7 cell lines were transfected with 5 µg pEGFP-BRCA1
1634-–1863 
(pEGFP-CTD) DNA using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. G418 (Sigma-Aldrich) was used as a selection 
drug at 800 µg/ml. Established stable CHO–EGFP-CTD and MCF-7–EGFP-
CTD cell lines were cell sorted according to expression levels and referred 
to as CHO-High and MCF-7–High for high and CHO-Low for low expres-
sion levels.
The MCF-7 cell line was transfected with 5 µg of full-length BRCA1-
pIRES2-EGFP and full-length BRCA1 with point mutation I26A-pIRES2-EGFP 
plasmid DNA using Lipofectamine 2000 according to the manufacturer’s 
instructions. G418 was used as a selection drug at 600 µg/ml.
To generate stable BRCA1-reconstituted HCC1937 cells, HCC1937 
cells were electroporated with full-length BRCA1-pIRES2-EGFP, full-length 
BRCA1 with point mutation I26A-pIRES2-EGFP (provided by X. Yu, Mayo 
Clinic, Rochester, MN), or pEGFP-CTD DNA using an electroporation system JCB • VOLUME 192 • NUMBER 3 • 2011   510
(1:300; Jackson ImmunoResearch Laboratories, Inc.), and donkey anti–
goat Alexa Fluor 647 (1:300; Invitrogen). For FRET, we used anti-pSer988 
BRCA1 (1:50; Santa Cruz Biotechnology, Inc.), anti-ERM (1:100), and 
anti–human  transferrin  receptor  (1:100;  Invitrogen)  antibodies  labeled 
with donkey anti–goat Alexa Fluor 488 (1:500), donkey anti–rabbit Cy3 
(1:300; Jackson ImmunoResearch Laboratories, Inc.), and donkey anti–
mouse Cy3 (1:300; Jackson ImmunoResearch Laboratories, Inc.), respec-
tively. As a positive control for FLIM, we used goat polyclonal anti-GFP 
antibody (1:1,000; Abcam) and donkey anti–goat Cy3 (1:300; Jackson 
ImmunoResearch Laboratories, Inc.).
Cryoimmuno-EM
HeLa cells were seeded and incubated at 37°C for a few hours. When they 
started to spread, cells were treated with 150 nM PMA for 90 min at 
37°C, fixed, and processed for cryoimmuno-EM as previously described 
(Coene et al., 2005). In brief, cells were fixed in 4% PFA/250 mM Hepes, 
pH 7.4, for 1 h at RT, embedded in 10% gelatin, and processed for cryo-
sectioning. Primary antibodies were rabbit anti-ERM (1:10; Cell Signaling 
Technology) and mouse anti-BRCA1 Ab4 (1:5; Oncogene Science–Merck 
Chemicals). Secondary antibodies were goat anti–rabbit 10-nm gold and 
goat anti–mouse 5-nm gold conjugates (BB International). Images were col-
lected on an electron microscope (Tecnai 12; FEI).
FLIM analysis
A microscope (Eclipse TE300; Nikon) incorporated in an imaging system 
(Radiance 2000 MP; Bio-Rad Laboratories) was used. A pulsed laser beam 
of 950 nm was obtained from a mode-locked Ti:Sapphire laser (Mira 900; 
Coherent, Inc.) for multiphoton excitation. Fluorescence lifetimes of EGFP 
were recorded using the direct detection system (Bio-Rad Laboratories) with 
a photomultiplier tube (H5783P; Hamamatsu) optimized for photon count-
ing and FLIM and a fast-time–correlated single-photon–counting acquisition 
board (SPC-830; Becker & Hickl). Lifetime images were collected at 512 × 
512 pixels with a 100-s scanning time and analyzed with SPCImage soft-
ware (Becker & Hickl). Within SPCImage, mask polygons were drawn 
around regions of interest (ROIs), and binning was set to give an initial 
photon count level of ≥1,000. EGFP lifetimes within the cells were analyzed 
by matrix calculation on a pixel-by-pixel basis. A multiexponential decay 
model was used, as this gave the lowest 
2 value and the best fit. Lifetime 
histograms (t1) were exported to and analyzed in Excel (Microsoft). The 
EGFP lifetime in the absence of an acceptor was used to determine FRET 
efficiencies using the formula 100 × [1  (t1/tunquenched EGFP)]. The acceptor 
used was Cy3, which was used to detect EGFP (positive control) or ERM.
FRET analysis
FRET using the acceptor photobleaching method (Kenworthy, 2001) was 
performed as previously described (Malhas et al., 2009). This was per-
formed on PMA-treated fixed cells after immunolabeling of ERM using anti-
ERM antibody (1:100) and donkey anti–rabbit Cy3 as the acceptor and 
endogenous BRCA1 using Ser988 and donkey anti–goat conjugated to   
Alexa Fluor 488 as the donor. As a negative control, we used the same 
BRCA1–Alexa Fluor 488 donor but a mouse anti–human transferrin recep-
tor primary antibody labeled with a Cy3-conjugated secondary antibody 
as an acceptor. An ROI containing membrane ruffles was selected, and 
both the donor and acceptor were detected for five scans. The ROI was 
then bleached with the 543-nm laser at 100% laser power. This was fol-
lowed by scanning to detect any changes in the acceptor and donor in-
tensities. FRET efficiency was then calculated using the following formula: 
100 × [1  (Ib/Ia)], in which Ib and Ia are the intensities of the donor before 
and after bleaching, respectively. Difference maps were calculated by sub-
tracting “before” pixel values from ”after” pixel values and rescaling to fill 
the 8-bit histogram range (which required a scaling factor of 2.0).
PMA and cytochalasin B treatment
HeLa cells were transfected with pEGFP-CTD as described (see Immuno-
fluorescence) and treated with 150 nM PMA for 90 min at 37°C. 20 µM 
cytochalasin B (Sigma-Aldrich) was added for 2 h at 37°C. Coverslips 
were fixed and further processed for immunofluorescence as described 
(see Immunofluorescence).
Competition and displacement
CHO-WT and CHO-High cells were fixed and immunostained with TRITC-
phalloidin and anti-Ser988 BRCA1 antibody as described in Immunofluores-
cence. Confocal z stacks were obtained using an LSM 510 META and a 63× 
oil lens, NA 1.4. Adjustments of brightness and contrast were applied using 
Photoshop. To quantify the displacement, a journal (macro) was written in which 
we measured the proportion of overlapping actin and anti-BRCA1 staining in 
West Dura Extended Duration Substrate kit (Thermo Fisher Scientific). Images 
were taken on an imaging system (ULTima16si Pro; Isogen Life Science).
Plasmids
The tubulin sequence was excised from an EGFP-tubulin vector (Takara Bio 
Inc.) by XhoI and XbaI digest (Roche). BRCA1 primers, including XhoI and 
XbaI restriction side ends, used in this study were BRCA1 (1,634–1,863 
aa), 5-GGCTGTCTAGAGTCAGTAGTGGCTGTG-3, and BRCA1 (1,634–
1,863 aa), 5-AGATCTCGAGAGAAGCCAGAATTGACAGC-3. DNA 
template pFLAG-YFP–full-length BRCA1 plasmid (gift from B. Henderson, 
Westmead Hospital, Sydney, Australia) was used. Inserts were digested 
with XhoI and XbaI, ligated in the vector, and transformed in Top10F’, and 
minipreps of the obtained colonies were prepared according to routine 
procedures. Sequence analysis was performed using the following prim-
ers: GFP forward, 5-CATGGTCCTGCTGGAGTTCGTG-3, and SV40 re-
verse, 5-GGACAAACCACAACTAGAATGC-3. The control pEGFP-NTA 
plasmid was a gift from Q. Sattentau (Dunn School of Pathology, Oxford, 
England, UK) and J. Komano (AIDS Research Center, Tokyo, Japan). Plas-
mids were transformed in DH5-, and maxipreps of obtained colonies 
were prepared according to routine procedures. The control EGFP-neo was 
obtained from B. Wickstead (Dunn School of Pathology, Oxford, England, 
UK) by cutting pVP22 (Invitrogen) with HindIII–KpnI and ligating in EGFP 
from pGad8–VSG-S8 (Wickstead et al., 2003). The EGFP-centrin plasmid 
was made in house (D.J. Vaux).
LC-MS/MS
LC-MS/MS sample preparation and analysis were performed as follows: 
bands/spots were excised and diced. Gel fragments were destained using 
25 mM ammonium bicarbonate (Fluka) in 50:50 double-distilled water/
acetonitrile (HPLC grade; Sigma-Aldrich) followed by dehydration in 100% 
acetonitrile and vacuum drying (Speedvac). Proteins were reduced with   
10 mM DTT and alkylated with 55 mM iodoacetamide. 200 ng trypsin 
(Promega) in 20 µl of 25-mM ammonium bicarbonate was added to the gel 
pieces, and proteins were digested at 37°C overnight. Digestion was stopped 
with formic acid (Fluka) to a concentration of 0.1%, and peptides were 
extracted. Supernatants were pooled and evaporated to dryness. Peptides 
were resuspended in 0.1% formic acid and stored at 20°C before analy-
sis. LC-MS/MS was performed on a mass spectrometer (Q-TOF Micro; 
Micromass) coupled to a capillary HPLC system (Waters). Proteins were 
identified by searching data files against Mascot (Matrix Science).
Immunofluorescence
HeLa, ECV304, and HCC1937 cells were either cultured and transfected 
with 5 µg pEGFP-CTD/pEGFP-centrin/pEGFP-neo DNA using Lipofectamine 
2000 according to the manufacturer’s instructions or cultured and pre-
pared  for  immunofluorescence  as  previously  described  (Coene  et  al., 
2005). In brief, cells were seeded onto glass coverslips, grown until 60% 
confluence, transfected or not transfected, and fixed in 4% (vol/vol) PFA 
and 250 mM Hepes, pH 7.4, for 20 min at RT. Coverslips were quenched 
in 50 mM NH4Cl in PBS for 10 min, permeabilized in 0.5% (vol/vol) Triton 
X-100 in PBS for 5 min, and blocked in 0.4% (vol/vol) fish skin gelatin 
(FSG; Sigma-Aldrich) in PBS for 30 min at RT. The primary antibodies were 
diluted in 0.4% (vol/vol) FSG in PBS and incubated for 1 h at RT. The 
Ser988 and Ser1497 anti-BRCA1 antibodies were incubated at 37°C for 
1 h. Secondary antibodies were diluted in 0.4% (vol/vol) FSG in PBS and 
incubated for 1 h at RT. Washes were performed in PBS. Coverslips were 
rinsed in distilled water and mounted in Mowiol (Mowiol 4–88; Hoechst 
AG) in 0.2-M Tris-HCl, pH 8.5, supplemented with 0.1 µg/ml DAPI. The 
images were taken on a laser-scanning microscope (LSM 510 META; Carl 
Zeiss, Inc.) using a 63× oil lens, NA 1.4. Adjustments of brightness and 
contrast were applied using Photoshop (Adobe). For the competition and 
displacement assay, z stacks were taken with a 0.3-µm-thick optical section 
and a typical pixel size of 0.1 or 0.2 µm.
For some experiments, coverslips were rinsed with a jet of PBS di-
rected from a wash bottle to provide mechanical shear stress that disrupted 
a proportion of the cells, leaving adherent membrane sheets behind. For 
other  experiments,  saponin  treatment  was  performed  as  previously  de-
scribed (Beranger et al., 1994).
Primary antibody dilutions used in this study were anti-BRCA1 anti-
bodies Ab5 (1:50), Ser988 (1:50), Ser1497 (1:50), anti-ERM antibody 
(1:100; Cell Signaling Technology), 0.1 µg/ml TRITC-phalloidin (Sigma- 
Aldrich), and anti-FAK (1:50; BD). Secondary antibodies used were don-
key anti–mouse Alexa Fluor 488 (1:500), donkey anti–goat Alexa Fluor 
488 (1:500; both are in-house–labeled Jackson ImmunoResearch Labora-
tories, Inc. secondary antibodies using an Alexa Fluor 488–labeling kit from 
Invitrogen), donkey anti–rabbit Cy5 (1:500), donkey anti–mouse Cy5 511 BRCA1 regulates cell spreading and motility • Coene et al.
all sections; STDB = background SD in each section averaged over all sec-
tions. (e) The fluorescence distribution is obtained over the whole image in 
each section: minimum = (MeanB + n × STDB); n = 3 (channel A) and   
1 (channel B; selectable by user); maximum = highest intensity in image; 
MeanF = mean of fluorescence distribution averaged over all sections; 
STDF = SD of fluorescence distribution averaged over all sections. (f) A fluores-
cence threshold is used to include just the bright focal signal: ThresholdF = 
MeanF + m × STDF; m = 0.5 (all channels). (g) ThresholdF is subtracted from 
the image. (h) The two image channels are merged after subtracting each 
threshold. (i) A 2D region for colocalization measurement is drawn and 
applied to all sections. (j) The colocalization percentage is obtained within 
the defined region for each image: IA = total intensity of all pixels in chan-
nel A; IAB = total intensity of all pixels in channel A with nonzero values in 
channel B; IAB/IA × 100% = percentage of channel A overlying nonzero 
channel B intensity. (k) Colocalization of channel B on channel A is esti-
mated as IBA, IB, and IBA/IB. (l) The colocalization percentage as a function 
of focus (z) is found for the entire stack: IAB(z)/IA(z) = colocalization per-
centage for section (z). (m) Threshold values and all the colocalization pa-
rameters are recorded in text files.
MetaMorph wound-healing macro
This is a description of the algorithm used in the MetaMorph journal 
IWA_1_02.jnl to estimate closure and wound edge roughness in phase con-
trast time-lapse images of a closing in vitro wound. The method gives two 
values that are estimates for (a) the mean width of the wound and (b) the 
combined length of lines traced around both wound edges (reduced perim-
eter). Values are derived for each time point. (a) The wound orientation 
was determined interactively (one angle for the whole stack). (b) The image 
stack was rotated to bring the axis horizontal (aligned in X). (c) A four-pass 
filter was applied to all time points to enhance cell edges using the following 
four kernels sequentially: kernel 1 (5, 5, 5; 3, 0, 3; 3, 3, 3), ker-
nel 2 (5, 5, 3; 5, 0, 3; 3, 3, 3), kernel 3 (5, 3, 3; 5, 3, 3; 
5, 3, 3), and kernel 4 (3, 3, 3; 5, 0, 3; 5, 5, 3). (d) A (se-
quential) Lomo filter (2-pixel-diam circle) reduced noise and joined touch-
ing cells. (e) A background region was defined within the wound area. 
(f) A threshold was determined from intensities in the background of each 
time point: threshold = (1 + n) × (mean background); n = 1 was empirically 
determined to clearly define the wound edge and kept constant in all 
wounds analyzed. (g) The wound area in each time point was found by the 
MetaMorph  immunofluorescence  tool.  (h)  Immunofluorescence  always 
found a single object >10,000 pixels in area above the threshold. (i) The 
mean wound width and a reduced perimeter of the wound area were de-
termined: width = (wound area)/(wound length); (reduced perimeter) = 
(perimeter of wound area)  2 × width. (j) The threshold value, width, and 
reduced perimeter were written into an ASCII (American Standard Code 
for Information Interchange) file.
Online supplemental material
Fig. S1 shows a schematic presentation of the BRCA1 BRCT domains, cryo-
immuno-EM of PMA-stimulated HeLa cells, a Western blot of CHO cells, 
and spreading of CHO-WT versus CHO-High cells. Fig. S2 shows EGFP-
CTD and endogenous BRCA1 colocalization with F-actin and ERM. Fig. S3 
shows endogenous BRCA1 colocalization with F-actin and ERM. Fig. S4 
shows that EGFP-CTD is present in focal adhesion plaques. Fig. S5 shows 
EGFP-protein distribution after saponin treatment. Fig. S6 shows colocaliza-
tion of EGFP-CTD, F-actin, and FAK after saponin treatment. Video 1 shows 
PM dynamics. Video 2 shows loss of cell–cell contacts and enhanced inva-
sion capacity in wound healing. Video 3 shows wound healing in CHO-WT 
versus CHO-High. Table S1 shows protein identification by mass spectrom-
etry from SDS-PAGE. Table S2 shows protein identification by mass spec-
trometry from 2D gel spots. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201004136/DC1.
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dual-channel immunofluorescence images using simple overlap parameters 
derived by Manders et al. (1993). We used the standard implementation of 
this parameter in the colocalization function of an image-processing pro-
gram (MetaMorph; MDS Analytical Technologies; see MetaMorph colocal-
ization macro for colocalization journal details). The percentage of values 
for endogenous BRCA1 overlap with F-actin was obtained for each plane in 
a z stack. For each z stack, only the colocalization values above a threshold 
cutoff (10% of the maximum value of all IF-actin values in a specific z stack) 
were taken into account. Colocalization values of seven individual z stacks 
per cell type were pooled and plotted with corresponding means. Unpaired 
two-tailed t test with Welch’s correction and nonparametric two-tailed 
Mann–Whitney test were performed. For the images in Fig. 5 B, z stacks re-
sulting from this analysis were displayed as mean intensity z projections.
Cell spreading
CHO-WT, CHO-High, and CHO-Low cells were seeded in equal densities 
(1–3 × 10
5 cells per well), fixed 3 h after seeding, mounted in Mowiol sup-
plemented with DAPI, and imaged on a laser-scanning microscope (LSM 5 
Pascal; Carl Zeiss, Inc.) using a 10× objective with NA 0.45. Phase con-
trast and EGFP images of five random fields on the coverslip were taken. 
The percentage of spread out cells per field was calculated. The percent-
age values for five fields from each of three independent experiments were 
pooled, averaged, and plotted with corresponding SDs after confirming no 
significant difference in variance for a condition between experiments 
using an F test. t tests were calculated. The area of the spread out cells versus 
rounded-up cells was measured using the Trace Region tool and Show Re-
gion Statistics option in MetaMorph software.
Single-cell motility
All cell lines were seeded in low densities in dishes (MatTek Corporation). 
24 h after seeding, the cells were imaged on an LSM 5 Pascal system using 
a 10× objective with NA 0.45. Phase contrast and EGFP images of four 
random fields in the dish were taken per cell type. Each field was imaged 
over a time period of 1 h at 2-min intervals. For each cell line, 15 cells per 
field were manually tracked over 30 time points using the Track Points op-
tion in MetaMorph software. The mean speed of all 60 cells over 30 time 
points was calculated per cell type with corresponding t tests. For Fig. 8 C, 
the mean speed of all cells from two independent setups (120 cells) over 30 
time points was calculated per cell type. The individual speed values per 
field, all in micrometers per minute, were grouped in bins ranging from 1 to 
5 at 0.5 intervals for CHO cell lines, ranging from 1 to 10 at single intervals 
for MCF-7, MCF-7–-High, MCF-7–WT, MCF-7–I26A, HCC1937, HCC1937 + 
WT BRCA1, and HCC1937-I26A cell lines, ranging from 1 to 5 at single 
intervals for HCC1937–EGFP-CTD, and ranging from 0 to 2 at 0.2 intervals 
for HeLa-EGFP-centrin, and the frequency per bin was determined.
The mean of all frequencies per bin per cell type and corresponding 
SDs were calculated and plotted. To display the individual cell tracks, the 
Track Objects option in MetaMorph software was used.
Wound healing
CHO-WT, unsorted CHO–EGFP-CTD, and CHO-High cells were seeded in 
MatTek  dishes  and  grown  to  confluence.  Each  cell  layer  was  scrape 
wounded and imaged on an LSM 510 META microscope using the Multi 
Time Series software option. Phase contrast and EGFP images of four ran-
dom wounds in the dish were recorded over a time period of 12 h at 2-min 
intervals. The wound perimeter was analyzed over time in a standardized 
way using an in-house analysis subroutine (see MetaMorph wound-healing 
macro for wound-healing MetaMorph journal details). For each two con-
secutive time points, the change in wound perimeter (width and length cor-
rected) was calculated, summed, and referred to as the PVI. For each cell 
type, seven wounds from different experiments were analyzed using this 
journal, and the obtained PVI values per cell type were plotted in a scatter 
dot plot with the corresponding means. Nonparametric two-tailed Mann–
Whitney U tests were performed.
MetaMorph colocalization macro
This  is  a  description  of  the  algorithm  used  in  the  MetaMorph  journal 
Coloc_003_02.jnl. The method gives two values showing the percentage 
of fluorescence (above a defined threshold) in each channel (of a two-channel 
z-stack image) that occupies the same volume (pixel by pixel) as fluores-
cence (above a defined threshold) in the other channel. (a) It is assumed 
that there is no significant bleed through between channels. (b) It is as-
sumed images have been filtered to reduce any significant noise. (c) It is 
assumed that each pixel represents a sum of background + fluorescence. 
(d) The background distribution is obtained from a background region in 
each section: MeanB = background mean in each section averaged over JCB • VOLUME 192 • NUMBER 3 • 2011   512
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